Lancet Neurol 10(9):819828
received funding from the European Unions Horizon Europe research and innovation programme through the NADIS project (#101073251)
A platform with a wider medication menu, deeper GLP-1 specialization, and flexible treatment options is better positioned to support the full arc of that journey
The total glucose-lowering effect of TRESIBA over 24 hours measured in a euglycemic clamp study after 8 days of once-daily administration in patients with type 1 diabetes increases approximately in proportion to the dose for doses between 0.4 units/kg to 0.8 units/kg
boulardii : Clues on host survival and probiotic activity based on promoter sequence variability
Therefore, from the maximum dose of 2.4mg, the patient stays on this dose for 4 weeks, then gets reduced to 1.7mg, then 1mg, then 0.5mg, then finally 0.25mg for 4 weeks, and then stops treatment